1. Home
  2. ENOV vs ATAI Comparison

ENOV vs ATAI Comparison

Compare ENOV & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enovis Corporation

ENOV

Enovis Corporation

HOLD

Current Price

$23.35

Market Cap

1.4B

Sector

Industrials

ML Signal

HOLD

ATAI

ATAI Life Sciences N.V.

HOLD

Current Price

$3.70

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENOV
ATAI
Founded
1995
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Fluid Controls
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.3B
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
ENOV
ATAI
Price
$23.35
$3.70
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
8
Target Price
$48.75
$15.13
AVG Volume (30 Days)
795.4K
4.1M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$308,000.00
Revenue This Year
$6.36
N/A
Revenue Next Year
$5.31
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$21.00
$1.15
52 Week High
$36.82
$6.73

Technical Indicators

Market Signals
Indicator
ENOV
ATAI
Relative Strength Index (RSI) 51.18 51.83
Support Level $21.33 $3.60
Resistance Level $23.57 $4.30
Average True Range (ATR) 1.12 0.20
MACD -0.01 0.01
Stochastic Oscillator 62.17 66.93

Price Performance

Historical Comparison
ENOV
ATAI

About ENOV Enovis Corporation

Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.

About ATAI ATAI Life Sciences N.V.

AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.

Share on Social Networks: